Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171)

Ann Oncol. 2008 Feb;19(2):397-8; author reply 398. doi: 10.1093/annonc/mdm577.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Administration, Oral
  • Biomarkers, Tumor / blood*
  • Bone Neoplasms / blood
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary*
  • Breast Neoplasms / blood
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Cohort Studies
  • Collagen Type I / blood
  • Collagen Type I / drug effects
  • Diphosphonates / administration & dosage*
  • Female
  • Humans
  • Ibandronic Acid
  • Imidazoles / administration & dosage*
  • Infusions, Intravenous
  • Osteocalcin / blood
  • Peptides / blood
  • Peptides / drug effects
  • Procollagen / blood
  • Procollagen / drug effects
  • Prognosis
  • Sensitivity and Specificity
  • Zoledronic Acid

Substances

  • Biomarkers, Tumor
  • Collagen Type I
  • Diphosphonates
  • Imidazoles
  • Peptides
  • Procollagen
  • collagen type I trimeric cross-linked peptide
  • Osteocalcin
  • Zoledronic Acid
  • Ibandronic Acid